Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 132


Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma.

Han SX, Bai E, Jin GH, He CC, Guo XJ, Wang LJ, Li M, Ying X, Zhu Q.

J Immunol Res. 2014;2014:261365. doi: 10.1155/2014/261365. Epub 2014 Apr 22.


Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.

Tu K, Yang W, Li C, Zheng X, Lu Z, Guo C, Yao Y, Liu Q.

Mol Cancer. 2014 May 17;13:110. doi: 10.1186/1476-4598-13-110.


RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.

Ahn EY, Kim JS, Kim GJ, Park YN.

Mol Cancer Res. 2013 Jul;11(7):748-58. doi: 10.1158/1541-7786.MCR-12-0665. Epub 2013 Apr 17.


Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma.

Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM.

Cancer. 2009 Oct 1;115(19):4576-85. doi: 10.1002/cncr.24495.


Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma.

Han SX, Wang JL, Guo XJ, He CC, Ying X, Ma JL, Zhang YY, Zhao Q, Zhu Q.

J Immunol Res. 2014;2014:262385. doi: 10.1155/2014/262385. Epub 2014 Apr 17.


High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma.

Li M, Luo RZ, Chen JW, Cao Y, Lu JB, He JH, Wu QL, Cai MY.

J Transl Med. 2011 Jan 5;9:5. doi: 10.1186/1479-5876-9-5.


An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.

Hayashi H, Higashi T, Yokoyama N, Kaida T, Sakamoto K, Fukushima Y, Ishimoto T, Kuroki H, Nitta H, Hashimoto D, Chikamoto A, Oki E, Beppu T, Baba H.

Cancer Res. 2015 Nov 15;75(22):4985-97. doi: 10.1158/0008-5472.CAN-15-0291. Epub 2015 Sep 29.


Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma.

Kong SY, Park JW, Kim JO, Lee NO, Lee JA, Park KW, Hong EK, Kim CM.

J Cancer Res Clin Oncol. 2009 Aug;135(8):1091-8. doi: 10.1007/s00432-009-0549-9. Epub 2009 Jan 31.


Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma.

Chao J, Zhang XF, Pan QZ, Zhao JJ, Jiang SS, Wang Y, Zhang JH, Xia JC.

Med Oncol. 2014 Aug;31(8):102. doi: 10.1007/s12032-014-0102-9. Epub 2014 Jul 4.


Expression of cystathionine beta-synthase is downregulated in hepatocellular carcinoma and associated with poor prognosis.

Kim J, Hong SJ, Park JH, Park SY, Kim SW, Cho EY, Do IG, Joh JW, Kim DS.

Oncol Rep. 2009 Jun;21(6):1449-54.


Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation.

Li H, Wang S, Wang G, Zhang Z, Wu X, Zhang T, Fu B, Chen G.

Dig Surg. 2014;31(6):468-78. doi: 10.1159/000370252. Epub 2015 Jan 22.


Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells.

Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W, Zhu Q.

PLoS One. 2013 Jun 10;8(6):e65539. doi: 10.1371/journal.pone.0065539. Print 2013.


High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy.

Lv Y, Wang W, Jia WD, Sun QK, Huang M, Zhou HC, Xia HH, Liu WB, Chen H, Sun SN, Xu GL.

Eur J Surg Oncol. 2013 Oct;39(10):1129-35. doi: 10.1016/j.ejso.2013.06.023. Epub 2013 Jul 31.


High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients.

Cai MY, Hou JH, Rao HL, Luo RZ, Li M, Pei XQ, Lin MC, Guan XY, Kung HF, Zeng YX, Xie D.

Mol Med. 2011 Jan-Feb;17(1-2):12-20. doi: 10.2119/molmed.2010.00103. Epub 2010 Sep 10.


Expression of ADAM8 and its clinical values in diagnosis and prognosis of hepatocellular carcinoma.

Jiang C, Zhang Y, Yu HF, Yu XT, Zhou SJ, Tan YF.

Tumour Biol. 2012 Dec;33(6):2167-72. doi: 10.1007/s13277-012-0477-1. Epub 2012 Sep 1.


MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties.

Liu AM, Poon RT, Luk JM.

Biochem Biophys Res Commun. 2010 Apr 9;394(3):623-7. doi: 10.1016/j.bbrc.2010.03.036. Epub 2010 Mar 10.


Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma.

Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, Ladu S, Singer S, Pinna F, Gretz N, Sticht C, Tomasi ML, Delogu S, Evert M, Fan B, Ribback S, Jiang L, Brozzetti S, Bergmann F, Dombrowski F, Schirmacher P, Calvisi DF, Breuhahn K.

Gastroenterology. 2013 Jun;144(7):1530-1542.e12. doi: 10.1053/j.gastro.2013.02.009. Epub 2013 Feb 16.


NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification.

Zhang Y, Fan Y, Mei Z.

Cancer Epidemiol. 2012 Oct;36(5):e294-9. doi: 10.1016/j.canep.2012.05.012. Epub 2012 Jun 23.


The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.

Chen D, Xing W, Hong J, Wang M, Huang Y, Zhu C, Yuan Y, Zeng W.

Ann Surg Oncol. 2012 Oct;19(11):3556-65. doi: 10.1245/s10434-012-2396-1. Epub 2012 May 17.


Dysregulated expression of dickkopfs for potential detection of hepatocellular carcinoma.

Fatima S, Luk JM, Poon RT, Lee NP.

Expert Rev Mol Diagn. 2014 Jun;14(5):535-48. doi: 10.1586/14737159.2014.915747. Epub 2014 May 9. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk